Whitehawk Therapeutics, Inc.
WHWK · XNASCIK 1422142fmd_1F9TQ3T3HAZ0A3Q4MEBNEC7AEV制造业 · 医药制剂模板: 标准
覆盖范围: 2008年1月01日 至 2026年9月30日，共 68 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | 20 | 0 | 14 | 14 | 15 | 24 | 26 | 7 |
| 营业成本 | – | – | – | – | – | 0 | 1 | 3 | 3 | 1 |
| 信用损失准备 | – | – | – | – | 0 | 0 | – | – | – | – |
| 毛利润 | – | – | – | – | – | 14 | 14 | 22 | 23 | 6 |
| 研发费用 | 11 | 12 | 18 | 13 | 15 | 20 | 33 | 49 | 51 | 91 |
| 销售、一般及管理费用 | – | – | – | – | – | 19 | 40 | 45 | 37 | 30 |
| 营业费用合计 | 17 | 21 | 31 | 24 | 17 | 112 | – | – | – | – |
| 营业利润 | (17) | (21) | (11) | (24) | (3) | (111) | (63) | (72) | (67) | (114) |
| 利息费用 | 0 | – | – | – | 1 | 1 | 0 | 0 | 0 | 0 |
| 利息及投资收益 | – | – | – | – | 0 | 0 | 2 | 6 | 4 | 6 |
| 其他营业外收入（支出） | (0) | (0) | 1 | 1 | 2 | 1 | 2 | 6 | 4 | 94 |
| 税前利润 | – | – | – | – | (3) | (110) | (61) | (66) | (64) | (21) |
| 所得税费用 | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | – | – | – | – | (3) | (110) | (61) | (66) | (64) | (21) |
| 净利润 | (17) | (21) | (10) | (23) | (3) | (110) | (61) | (66) | (64) | (21) |
| 归属于普通股股东的净利润 | (21) | (22) | (10) | (23) | (4) | (111) | (61) | – | – | – |